Drug Profile
Nusinersen - Biogen/Ionis Pharmaceuticals
Alternative Names: BIIB 058; IONIS-SMNRx; ISIS-396443; ISIS-SMNRx; SpinrazaLatest Information Update: 03 Apr 2023
Price :
$50
*
At a glance
- Originator Genzyme Corporation; Isis Pharmaceuticals
- Developer Biogen; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference; Survival of motor neuron 2 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Spinal muscular atrophy
Most Recent Events
- 27 Sep 2022 Launched for Spinal muscular atrophy (In adolescents, In children, In infants, In neonates, In adults) in Canada (Intrathecal)
- 30 Aug 2022 The Canadian Agency for Drugs and Technologies in Health's (CADTH) announces their decision to not give reimbursement to adult patients with Spinal muscular atrophy (SMA) in Canada
- 15 Jun 2022 Final adverse events data from a phase II/III DEVOTE trial in Spinal muscular atrophy released by Biogen